A Phase 4 interventional study of peginterferon alfa-2a and ribavirin [Copegus] in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 15 sites in Brazil. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2016-07-25.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 42nd largest by enrollment, is one of 7 that started in 2011, is one of 48 in phase 4, and was the 63rd registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 20 · Phase 4 48
First in 2000; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 129 across the 83 interventional studies. Of the 75 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 83 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 32nd largest by enrollment of the 59 interventional ones that give a count, is one of 12 that started in 2011, is one of 29 in phase 4, and was the 53rd registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multi-center, open-label study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in relation to IL28-b gene expression in treatment-naïve patients with chronic hepatitis C genotype 1. Patients will receive Pegasys (180 mcg sc weekly) and Copegus ( 1'000 or 1'200 mg orally daily) for 48 weeks. Anticipated time of study treatment is 48 weeks, follow-up is 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: peginterferon alfa-2a · Drug: ribavirin [Copegus]
180 mcg sc weekly, 48 weeks
1'000 or 1'200 mg orally daily, 48 weeks
Percentage of Participants With Sustained Virological Response Rate in Relation to Interleukin 28B Expression
Participants with sustained virological response (SVR) rate in relation to interleukin 28B expression were reported. SVR rate is defined as the percentage of participants with undetectable HCV Ribonucleic acid (RNA), measured at least 24 weeks after the end of treatment (48 weeks) in terms of the expression profile of Interleukin 28B (IL-28B) (CC, CT or TT) in participants with genotype 1 hepatitis C virus (HCV) chronic infection. Participants with detectable HCV RNA or without measurement at the end of the follow-up period were considered as non-responders.
Time frame: At Week 72
Percentage of Participants With Incidence of Anemia
Anemia is a condition marked by a deficiency of red blood cells (RBCs) or of hemoglobin (Hb) in the blood, resulting in pallor and weariness anemia (Hb \< 11 gram per decilitre (g/dL) for women and Hb \< 12 g/dL for men). Incidence of anemia was calculated by dividing the number of participants who experienced the event by the number of participants in the safety population.
Time frame: Up to Week 72
Number of Participants With Viral Response Rate (Rapid/Early/End of Treatment) in Relation to IL28-B Expression
Viral Response rate (rapid/early/end of treatment) in relation to IL28-B expression (measured by the rate of non-detection of HCV RNA at treatment Weeks 4, 12, 24 and after the End of Treatment (EOT, i.e. Week 48) based on the expression profile of IL-28B (CC, CT or TT) were reported. Rapid virologic response (RVR) was defined as undetectable HCV RNA at treatment Week 4. Partial early virological response (pEVR) was defined as positive HCV viral load, but with a \>= 2 log10 international units (IU) per millilitre (mL) reduction at treatment Week 12 from Baseline (Week 0); Complete early virologic response (cEVR) was defined as undetectable HCV RNA at treatment Week 12; Virologic response at treatment Week 24 (VR 24) was defined as undetectable HCV RNA at treatment Week 24; Virologic response at end of treatment (EOT) was defined as undetectable HCV RNA at treatment Week 48; SVR at 24 weeks after end of treatment was defined as undetectable HCV RNA at 24 weeks after EOT.
Time frame: Weeks 4, 12, 24, 48, 60 and 72
Number of Participants With Sustained Virological Response and Occurrence of Anemia During The First Month of Treatment and After the First Month of Treatment
Participants with sustained virological response (SVR) and development of anemia during the first month and after the first month of treatment according to the different expression profiles of IL-28B were reported.
Time frame: Up to Week 72
Number of Participants With Viral Load Reduction (HCV-RNA Levels) at Week 4 and 12
Viral load reduction at Week 4 and Week 12 relative to the Baseline (Week 0) in terms of the expression profile of IL-28b was reported. The reduction was measured according to the following ranges: \< 1.0 log IU/ml; \>= 1.0 and \< 2.0 log IU/ml; \>= 2.0 and \< 3.0 log IU/ml; \>= 3.0 and \<4.0 log IU/ml; \>= 4.0 log IU/ml. Changes in viral load are usually reported as a log change (in powers of 10). For example, a two log decrease in viral load (2 Log10) is a decrease of 10\^2 or 100 times to the previously reported levels. N = number of participants, for Week 0 to Week 4 (n = 34, 68, 17) and Week 0 to Week 12 (n = 35, 69, 18) for CC, CT and TT genotypes respectively.
Time frame: From Baseline (Week 0) to Week 12
A total of 129 participants were enrolled from February 2011 to November 2012 at 14 study sites in Brazil.
| Milestone | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CT | Peginterferon Alfa-2a Plus Ribavirin With Genotype - TT |
|---|---|---|---|
| Started | 39 | 72 | 18 |
| Completed | 29 | 45 | 8 |
| Not completed | 10 | 27 | 10 |
| Withdrew: Adverse event | 2 | 4 | 2 |
| Withdrew: Protocol violation | 3 | 3 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 19 | 8 |
Participants with sustained virological response (SVR) rate in relation to interleukin 28B expression were reported. SVR rate is defined as the percentage of participants with undetectable HCV Ribonucleic acid (RNA), measured at least 24 weeks after the end of treatment (48 weeks) in terms of the expression profile of Interleukin 28B (IL-28B) (CC, CT or TT) in participants with genotype 1 hepatitis C virus (HCV) chronic infection. Participants with detectable HCV RNA or without measurement at the end of the follow-up period were considered as non-responders.
| Percentage of participants | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CT | Peginterferon Alfa-2a Plus Ribavirin With Genotype - TT |
|---|---|---|---|
| Percentage of Participants With Sustained Virological Response Rate in Relation to Interleukin 28B Expression | 63.2 (46.0 to 78.2) | 26.4 (16.7 to 38.1) | 33.3 (13.3 to 59.0) |
Anemia is a condition marked by a deficiency of red blood cells (RBCs) or of hemoglobin (Hb) in the blood, resulting in pallor and weariness anemia (Hb \< 11 gram per decilitre (g/dL) for women and Hb \< 12 g/dL for men). Incidence of anemia was calculated by dividing the number of participants who experienced the event by the number of participants in the safety population.
| Percentage of participants | Peginterferon Alfa-2a Plus Ribavirin |
|---|---|
| Percentage of Participants With Incidence of Anemia | 67.4 (58.6 to 75.4) |
Viral Response rate (rapid/early/end of treatment) in relation to IL28-B expression (measured by the rate of non-detection of HCV RNA at treatment Weeks 4, 12, 24 and after the End of Treatment (EOT, i.e. Week 48) based on the expression profile of IL-28B (CC, CT or TT) were reported. Rapid virologic response (RVR) was defined as undetectable HCV RNA at treatment Week 4. Partial early virological response (pEVR) was defined as positive HCV viral load, but with a \>= 2 log10 international units (IU) per millilitre (mL) reduction at treatment Week 12 from Baseline (Week 0); Complete early virologic response (cEVR) was defined as undetectable HCV RNA at treatment Week 12; Virologic response at treatment Week 24 (VR 24) was defined as undetectable HCV RNA at treatment Week 24; Virologic response at end of treatment (EOT) was defined as undetectable HCV RNA at treatment Week 48; SVR at 24 weeks after end of treatment was defined as undetectable HCV RNA at 24 weeks after EOT.
| participants | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CT | Peginterferon Alfa-2a Plus Ribavirin With Genotype - TT |
|---|---|---|---|
| RVR rate, Week 4 (n = 14) | 11 | 3 | 0 |
| pEVR rate, Week 12 (n = 33) | 4 | 24 | 5 |
| cEVR rate, Week 12 (n = 72) | 31 | 36 | 5 |
| VR rate, Week 24 (n = 87) | 31 | 46 | 10 |
| VR rate, EOT (Week 48) (n = 74) | 28 | 37 | 9 |
| VR rate, 12 weeks post-treatment (n = 50) | 25 | 19 | 6 |
| SVR rate, 24 weeks or more post-treatment (n = 49) | 24 | 19 | 6 |
Participants with sustained virological response (SVR) and development of anemia during the first month and after the first month of treatment according to the different expression profiles of IL-28B were reported.
| participants | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CT | Peginterferon Alfa-2a Plus Ribavirin With Genotype - TT |
|---|---|---|---|
| SVR with No anemia (n = 15, 20, 6) | 9 | 4 | 2 |
| In the first month of treatment (n = 10, 15, 2) | 6 | 3 | 0 |
| After the first month of treatment (n = 13, 37,10) | 9 | 12 | 4 |
Viral load reduction at Week 4 and Week 12 relative to the Baseline (Week 0) in terms of the expression profile of IL-28b was reported. The reduction was measured according to the following ranges: \< 1.0 log IU/ml; \>= 1.0 and \< 2.0 log IU/ml; \>= 2.0 and \< 3.0 log IU/ml; \>= 3.0 and \<4.0 log IU/ml; \>= 4.0 log IU/ml. Changes in viral load are usually reported as a log change (in powers of 10). For example, a two log decrease in viral load (2 Log10) is a decrease of 10\^2 or 100 times to the previously reported levels. N = number of participants, for Week 0 to Week 4 (n = 34, 68, 17) and Week 0 to Week 12 (n = 35, 69, 18) for CC, CT and TT genotypes respectively.
| participants | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CT | Peginterferon Alfa-2a Plus Ribavirin With Genotype - TT |
|---|---|---|---|
| Week 0 - Week 4 (<1.0 log10 UI / ml) | 0 | 26 | 10 |
| Week 0 - Week 4 (>=1.0 e < 2.0 log10 UI / ml) | 4 | 24 | 5 |
| Week 0 - Week 4 (>=2.0 e < 3.0 log10 UI / ml) | 9 | 13 | 1 |
| Week 0 - Week 4 (>=3.0 e < 4.0 log10 UI / ml) | 13 | 2 | 1 |
| Week 0 - Week 4 (>=4.0 log10 UI / ml) | 8 | 3 | 0 |
| Week 0 - Week 12 (<1.0 log10 UI / ml) | 0 | 1 | 3 |
| Week 0 - Week 12 (>=1.0 e < 2.0 log10 UI / ml) | 3 | 9 | 5 |
| Week 0 - Week 12 (>=2.0 e < 3.0 log10 UI / ml) | 5 | 11 | 3 |
| Week 0 - Week 12 (>=3.0 e < 4.0 log10 UI / ml) | 5 | 22 | 3 |
| Week 0 - Week 12 (>=4.0 log10 UI / ml) | 22 | 26 | 4 |
Collected over Up to Week 72. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Peginterferon Alfa-2a Plus Ribavirin | — | 6/129 (4.7%) | 125/129 (96.9%) |
| Event | Peginterferon Alfa-2a Plus Ribavirin |
|---|---|
| Chest painCardiac disorders | 1/129 |
| Optic ischaemic neuropathyEye disorders | 1/129 |
| Retinal vascular disorderEye disorders | 1/129 |
| Perianal erythemaGastrointestinal disorders | 1/129 |
| Hepatic encephalopathyNervous system disorders | 1/129 |
| Anxiety disorderPsychiatric disorders | 1/129 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/129 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/129 |
| Event | Peginterferon Alfa-2a Plus Ribavirin |
|---|---|
| HeadacheNervous system disorders | 55/129 |
| InfluenzaInfections and infestations | 54/129 |
| PyrexiaGeneral disorders | 48/129 |
| MyalgiaMusculoskeletal and connective tissue disorders | 42/129 |
| AnaemiaBlood and lymphatic system disorders | 41/129 |
| AstheniaGeneral disorders | 35/129 |
| NauseaGastrointestinal disorders | 32/129 |
| DiarrhoeaGastrointestinal disorders | 25/129 |
| InsomniaPsychiatric disorders | 25/129 |
| IrritabilityPsychiatric disorders | 25/129 |
Safety population included all enrolled participants who received at least one dose of any study medication.
| Age, Continuous(years) | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CT | Peginterferon Alfa-2a Plus Ribavirin With Genotype - TT | Total |
|---|---|---|---|---|
| Mean | 48.51 ± 12.71 | 50.43 ± 10.92 | 52.33 ± 10.22 | 50.12 ± 11.38 |
| Sex: Female, Male(Participants) | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC | Peginterferon Alfa-2a Plus Ribavirin With Genotype - CT | Peginterferon Alfa-2a Plus Ribavirin With Genotype - TT | Total |
|---|---|---|---|---|
| Female | 22 | 33 | 9 | 64 |
| Male | 17 | 39 | 9 | 65 |
The record gives a start of Feb 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a